TTY Biopharm Company Limited (TPEX:4105)
Taiwan · Delayed Price · Currency is TWD 83.70
-0.40 (-0.48%)
At close: Feb 11, 2026
TTY Biopharm Company Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 1,790 | 1,450 | 1,129 | 1,094 | 831.89 | 924.18 |
Depreciation & Amortization | 200.07 | 194.26 | 193.1 | 180.69 | 162.79 | 153.86 |
Other Amortization | 8 | 8.09 | 7.8 | 5.59 | 4.49 | 3.14 |
Loss (Gain) From Sale of Assets | 1.72 | 0.95 | 1.93 | 3.28 | 0.74 | 0.32 |
Asset Writedown & Restructuring Costs | 26.98 | 6.8 | 116.18 | 0.73 | 4.15 | 4.58 |
Loss (Gain) From Sale of Investments | -0.95 | - | 8.79 | - | 0.21 | -0.16 |
Loss (Gain) on Equity Investments | -399.01 | -400.05 | -131.34 | -116.38 | -135.18 | -162.87 |
Provision & Write-off of Bad Debts | 0.3 | 1.36 | -1.93 | 3.56 | 13.58 | -0.1 |
Other Operating Activities | 360.5 | 202.01 | 122.02 | 110.34 | 110.24 | -15.66 |
Change in Accounts Receivable | -343.38 | 35.07 | -116.16 | -95.4 | -114.32 | -36.42 |
Change in Inventory | 21.11 | -161.27 | -56.75 | -83.95 | 155.12 | -251.8 |
Change in Accounts Payable | 57.42 | -10.21 | 11.95 | 96.01 | -23.07 | -26.35 |
Change in Unearned Revenue | 4.14 | 20.11 | -18.89 | -6.64 | 23.48 | -0.39 |
Change in Other Net Operating Assets | 56.66 | 2.63 | -179.89 | 43.55 | 222.24 | -65.98 |
Operating Cash Flow | 1,784 | 1,349 | 1,085 | 1,236 | 1,256 | 526.35 |
Operating Cash Flow Growth | 58.98% | 24.33% | -12.17% | -1.64% | 138.69% | -56.49% |
Capital Expenditures | -135.64 | -125.16 | -78.35 | -91.52 | -60.32 | -168.11 |
Sale of Property, Plant & Equipment | 2.54 | 3.93 | 7.01 | 9.39 | 0.03 | 0.01 |
Cash Acquisitions | - | -242.87 | - | - | - | - |
Sale (Purchase) of Intangibles | -38.41 | -9.14 | -21.23 | -43.98 | -13.84 | -13.75 |
Investment in Securities | -73.92 | 128.18 | 168.55 | 34.68 | -14.1 | 308.82 |
Other Investing Activities | -45.05 | 1.49 | -78.62 | -41.7 | -80.56 | 20.26 |
Investing Cash Flow | -289 | -243.56 | -2.63 | -133.14 | -168.78 | 147.24 |
Short-Term Debt Issued | - | 8,050 | 10,280 | 10,890 | 5,400 | 5,400 |
Long-Term Debt Issued | - | 500 | 400 | 430 | - | 720 |
Total Debt Issued | 6,500 | 8,550 | 10,680 | 11,320 | 5,400 | 6,120 |
Short-Term Debt Repaid | - | -8,300 | -10,200 | -11,231 | -5,404 | -5,246 |
Long-Term Debt Repaid | - | -409.77 | -434.17 | -421.55 | -16.54 | -663.65 |
Total Debt Repaid | -6,809 | -8,710 | -10,634 | -11,653 | -5,421 | -5,910 |
Net Debt Issued (Repaid) | -308.82 | -159.77 | 45.83 | -332.62 | -20.54 | 210.35 |
Common Dividends Paid | -1,058 | -870.28 | -845.41 | -745.95 | -994.6 | -994.6 |
Other Financing Activities | -15.59 | -21.19 | -16.75 | -24.83 | -28.99 | -22.36 |
Financing Cash Flow | -1,383 | -1,051 | -816.33 | -1,103 | -1,044 | -806.61 |
Foreign Exchange Rate Adjustments | -56.61 | 97.02 | -2.66 | 135.85 | -44.91 | -65.41 |
Net Cash Flow | 55.57 | 151.6 | 263.7 | 135.07 | -1.48 | -198.43 |
Free Cash Flow | 1,648 | 1,224 | 1,007 | 1,144 | 1,196 | 358.25 |
Free Cash Flow Growth | 59.92% | 21.57% | -12.00% | -4.33% | 233.86% | -68.58% |
Free Cash Flow Margin | 25.35% | 20.77% | 18.29% | 22.61% | 26.37% | 8.49% |
Free Cash Flow Per Share | 6.62 | 4.91 | 4.04 | 4.59 | 4.80 | 1.44 |
Cash Interest Paid | 38.89 | 38.46 | 34.99 | 23.22 | 18.67 | 19.6 |
Cash Income Tax Paid | 379.08 | 297.06 | 283.71 | 277.92 | 220.22 | 311.47 |
Levered Free Cash Flow | 769.68 | 891.34 | 737.63 | 806.96 | 980.02 | 107.23 |
Unlevered Free Cash Flow | 793.75 | 915.25 | 759.62 | 821.24 | 991.87 | 119.36 |
Change in Working Capital | -204.05 | -113.67 | -359.75 | -46.44 | 263.45 | -380.95 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.